Cargando…

The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice

To clarify the effects of a dipeptidyl peptidase‐4 (DPP‐4) inhibitor on whole‐body energy metabolism, we treated mice fed a high‐fat diet (HFD) with teneligliptin, a clinically available DPP‐4 inhibitor. Teneligliptin significantly prevented HFD‐induced obesity and obesity‐associated metabolic disor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeda, Kenichiro, Sawazaki, Honami, Takahashi, Haruya, Yeh, Yu‐Sheng, Jheng, Huei‐Fen, Nomura, Wataru, Ara, Takeshi, Takahashi, Nobuyuki, Seno, Shigeto, Osato, Naoki, Matsuda, Hideo, Kawada, Teruo, Goto, Tsuyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6212644/ https://www.ncbi.nlm.nih.gov/pubmed/30410858 http://dx.doi.org/10.1002/2211-5463.12498

Ejemplares similares

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidase‐4 inhibitors
por: Nakamaru, Yoshinobu, et al.
Publicado: (2016)

Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor
por: Takahara, Yusuke, et al.
Publicado: (2018)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Reduces Aortic Damage from Hypercholesterolaemia in Apolipoprotein E-Deficient Mice
por: Zhang, Ying, et al.
Publicado: (2017)

Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes
por: Zilleßen, Pia, et al.
Publicado: (2016)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
por: Barchetta, Ilaria, et al.
Publicado: (2022)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki, Satoko, et al.
Publicado: (2020)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
por: Ito, Rika, et al.
Publicado: (2015)

Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19
por: Firneisz, Gábor
Publicado: (2023)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
por: Ideta, Takayasu, et al.
Publicado: (2015)

β-adrenergic Receptor Stimulation Revealed a Novel Regulatory Pathway via Suppressing Histone Deacetylase 3 to Induce Uncoupling Protein 1 Expression in Mice Beige Adipocyte
por: Yuliana, Ana, et al.
Publicado: (2018)

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis
por: Homma, Koichiro, et al.
Publicado: (2017)

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
por: Kim, Hae Jin, et al.
Publicado: (2019)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Neuronal Roles of the Multifunctional Protein Dipeptidyl Peptidase-like 6 (DPP6)
por: Malloy, Cole, et al.
Publicado: (2022)

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus
por: Cui, Jie, et al.
Publicado: (2013)

Reply to Firneisz: “Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19”
por: Lin, Shu-Hai, et al.
Publicado: (2023)

The effect of Dipeptidyl peptidase 4 (DPP-4) inhibitors on hemoglobin level in diabetic kidney disease: A retrospective cohort study
por: Zeng, Lingfeng, et al.
Publicado: (2023)

Identification of Dipeptidyl-Peptidase (DPP)5 and DPP7 in Porphyromonas endodontalis, Distinct from Those in Porphyromonas gingivalis
por: Nishimata, Haruka, et al.
Publicado: (2014)

Endoplasmic Reticulum Stress Impaired Uncoupling Protein 1 Expression via the Suppression of Peroxisome Proliferator-Activated Receptor γ Binding Activity in Mice Beige Adipocytes
por: Yuliana, Ana, et al.
Publicado: (2019)

Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients
por: Sarkar, Jit, et al.
Publicado: (2019)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

The Inhibitory Effects of New Zealand Pine Bark (Enzogenol(®)) on α-Amylase, α-Glucosidase, and Dipeptidyl Peptidase-4 (DPP-4) Enzymes
por: Lim, Wen Xin Janice, et al.
Publicado: (2022)

Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity
por: Hoshino, Yuki, et al.
Publicado: (2022)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s2ddnad3vf86okv4ireev1pt2p